Location History:
- Takasaki, JP (2011 - 2012)
- Fujioka, JP (2014)
Company Filing History:
3 out of 6 
1 out of 815 
1 out of 4 Years Active: 2011-2014
Title: Innovations by Tsutomu Seito: A Pioneer in Antibody Research
Introduction: Tsutomu Seito, an accomplished inventor based in Takasaki, Japan, has made significant contributions to the field of biomedicine. With a portfolio of three patents, his work primarily focuses on antibodies that have the potential to target specific conformations of amyloid proteins, which are crucial in diseases such as Alzheimer's.
Latest Patents: Tsutomu Seito's latest patents include notable innovations such as an antibody that recognizes a turn structure in amyloid β (Aβ). This invention provides a therapeutic method aimed explicitly at targeting Aβ with a specific turn structure found at amino acid positions 22 and 23. The patent also describes a medicinal composition containing this antibody, an assay kit for detecting toxic conformers of Aβ, and diagnostics for Alzheimer's disease. Another significant patent is for a monoclonal antibody that selectively recognizes OPN N-half without reacting to the full-length OPN. This antibody is characterized by its ability to identify a specific protein sequence and is intended for measuring OPN N-half, diagnosing related diseases, assessing their severity, and offering treatment methods.
Career Highlights: Tsutomu Seito has worked with prominent organizations, including Immuno-biological Laboratories Co., Ltd. and Kyoto University. His experience in these institutions has allowed him to deepen his expertise and contribute to critical advancements in antibody-based therapeutics.
Collaborations: Throughout his career, Tsutomu Seito has collaborated with esteemed colleagues such as Hiroko Kobayashi and Masahiro Hasegawa. These partnerships have fostered an environment of innovation and intellectual exchange, significantly contributing to the success of his research endeavors.
Conclusion: Tsutomu Seito stands out as a leading inventor in the field of antibody research, with a focus on targeting amyloid proteins linked to neurodegenerative diseases. His innovative patents pave the way for new therapeutic approaches and diagnostic tools, highlighting his commitment to advancing medical science.